The niemann-pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA

Molecular Therapy

Volumn 24, Issue 12, 2016, Pages 2100-2108

  Wang, Haitang ^a   Tam, Yuen Yi C ^a   Chen, Sam ^a   Zaifman, Josh ^a   Van Der Meel, Roy ^a,b   Ciufolini, Marco A ^a   Cullis, Pieter R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID NANOPARTICLE; NANOPARTICLE; NP 3 47; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN; LIPID; MEMBRANE PROTEIN; MOLECULAR LIBRARY; NPC1 PROTEIN, HUMAN; NPC1 PROTEIN, MOUSE; PROTEIN;

ACIDIFICATION; ANIMAL CELL; ARTICLE; CELL ORGANELLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENDOSOME; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LYSOSOME; MALE; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HELA CELL LINE; MOLECULAR LIBRARY; NIH 3T3 CELL LINE; PHARMACOLOGY; RAW 264.7 CELL LINE; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOSOMES; GENE SILENCING; HELA CELLS; HUMANS; LIPIDS; MEMBRANE GLYCOPROTEINS; MICE; NANOPARTICLES; NIH 3T3 CELLS; PROTEINS; RAW 264.7 CELLS; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES;

EID: 84994164431     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.179     Document Type: Article

References (29)

1. Wu, SY, Lopez-Berestein G, Calin GA, and Sood AK (2014). RNAi therapies: drugging the undruggable. Sci Transl Med 6: 240ps7.
2. Kanasty R, Dorkin JR, Vegas A, and Anderson D (2013). Delivery materials for siRNA therapeutics. Nat Mater 12: 967-977.
3. Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, et al. (2012). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1: e37.
4. Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du, X, et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51: 8529-8533.
5. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
6. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. (2013). Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking, and endosomal escape. Nat Biotechnol 31: 638-646.
7. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. (2013). Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31: 653-658.
8. Platt FM, Wassif C, Colaco A, Dardis A, Lloyd-Evans E, Bembi B, et al. (2014). Disorders of cholesterol metabolism, and their unanticipated convergent mechanisms of disease. Annu Rev Genomics Hum Genet 15: 173-194.
9. Côté, M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, et al. (2011). Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348.
10. Lu, F, Liang Q, Abi-Mosleh L, Das A, De Brabander JK, Goldstein JL, et al. (2015). Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export, and Ebola infection. Elife 4: e12177.
11. Zhigaltsev IV, Belliveau N, Hafez I, Leung AK, Huft J, Hansen C, et al. (2012). Bottom-up design, and synthesis of limit size lipid nanoparticle systems with aqueous, and triglyceride cores using millisecond microfluidic mixing. Langmuir 28: 3633-3640.
12. Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, and Cullis PR (2014). Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release 196: 106-112.
13. Broderick KE, Chan A, Lin F, Shen X, Kichaev G, Khan AS, et al. (2012). Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. Mol Ther Nucleic Acids 1: e11.
14. Griffiths G, Hoflack B, Simons K, Mellman I, and Kornfeld S (1988). The mannose 6-phosphate receptor, and the biogenesis of lysosomes. Cell 52: 329-341.
15. Ashfaq UA, Javed T, Rehman S, Nawaz Z, and Riazuddin S (2011). Lysosomotropic agents as HCV entry inhibitors. Virol J 8: 163.
16. Gillespie EJ, Ho, CL, Balaji K, Clemens DL, Deng G, Wang YE, et al. (2013). Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins, and viruses. Proc Natl Acad Sci USA 110: E4904-E4912.
17. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, and Tashiro Y (1991). Bafilomycin A1, a specific inhibitor of vacuolar-Type H(+)-ATPase, inhibits acidification, and protein degradation in lysosomes of cultured cells. J Biol Chem 266: 17707-17712.
18. Goldman SD, and Krise JP (2010). Niemann-Pick C1 functions independently of Niemann-Pick C2 in the initial stage of retrograde transport of membraneimpermeable lysosomal cargo. J Biol Chem 285: 4983-4994.
19. Luzio JP, Pryor PR, and Bright NA (2007). Lysosomes: fusion, and function. Nat Rev Mol Cell Biol 8: 622-632.
20. Akinc A, Querbes W, De, S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. (2010). Targeted delivery of RNAi therapeutics with endogenous, and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.
21. Eltoukhy AA, Sahay G, Cunningham JM, and Anderson DG (2014). Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles. ACS Nano 8: 7905-7913.
22. Wittrup A, Ai, A, Liu X, Hamar P, Trifonova R, Charisse K, et al. (2015). Visualizing lipid-formulated siRNA release from endosomes, and target gene knockdown. Nat Biotechnol 33: 870-876.
23. Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, et al. (2011). Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 19: 2186-2200.
24. Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, et al. (2012). Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer 131: E781-E790.
25. Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, et al. (2011). Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis, and inhibits angiogenesis in neuroblastoma. Mol Ther 19: 2201-2212.
26. Chen S, Zaifman J, Tam YYC, Zhigaltsev IV, Tama YK, Ciufolini MA, et al. (2016). Lipophilic dexamethasone prodrugs are potent suppressors of lipid nanoparticle mediated immune stimulation. Submitted.
27. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569.
28. Potapova TA, Sivakumar S, Flynn JN, Li, R, and Gorbsky GJ (2011). Mitotic progression becomes irreversible in prometaphase, and collapses when Wee1, and Cdc25 are inhibited. Mol Biol Cell 22: 1191-1206.
29. Cordelieres FP, and Bolte S (2008). In: Proceedings of the 2nd ImageJ User, and Developer Conference. pp. 174-181.